MedPath

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

Phase 3
Recruiting
Conditions
Hidradenitis Suppurativa
Interventions
Drug: Placebo
Registration Number
NCT06468228
Lead Sponsor
AbbVie
Brief Summary

Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in areas of the skin such as under the breasts, under armpits, inner thighs, groin and buttocks. This study will compare lutikizumab versus placebo for the treatment of adult and adolescent participants with moderate to severe HS .

Lutikizumab is an investigational drug being developed for the treatment of HS. During Period 1 of the study, participants will placed in 1 of 2 groups called treatment arms. There is a 1 in 2 chance that participants will be assigned to placebo. Around 1280 adult and adolescent participants with moderate to severe HS will be enrolled in the study at approximately 275 sites world wide. During Period 2, participants that were part of the lutikizumab treatment arm in Period 1 will be re-randomized to 1 of 2 lutikizumab treatment arms. Participants that were part of the Placebo arm in Period 1 will start Period 2 with an initiation of lutikizumab followed by a re-randomization to 1 of 2 lutikizumab treatment arms.

In Period 1, participants will receive subcutaneous injections of lutikizumab or placebo every week for 16 weeks. In Period 2, participants that were randomized to lutikizumab in Period 1 will receive subcutaneous injections of lutikizumab every week or every other week for 36-weeks. Participants that were randomized to the placebo arm in Period 1 will receive subcutaneous injections of lutikizumab every week for 16 weeks, then either every week or every other week for 20 weeks

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires and diaries.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
1280
Inclusion Criteria
  • Diagnosis of moderate to severe HS for at least 6 months prior to Baseline as determined by the investigator (i.e., through medical history and interview of participant).
  • Total abscess and inflammatory nodule (AN) count of ≥ 5 at Baseline
  • Hidradenitis suppurativa (HS) lesions present in at least two distinct anatomic areas at Baseline.
  • At least 1 anatomic area of HS involvement characterized as Hurley Stage II or higher at Baseline.
Exclusion Criteria
  • Any evidence of Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
  • Confirmed positive anti-HIV antibody (HIV Ab) test.
  • Evidence of active tuberculosis or meets tuberculosis exclusionary parameter

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Period 1LutikizumabParticipants will be randomized to either Lutikizumab Dose B at baseline followed by Lutikizumab Dose A, or a matching placebo dose equivalent for both, every week through Week 16 .
Period 2: Placebo to Lutikizumab Group Every Other WeekLutikizumabThe participants that were assigned Placebo in Period 1 and initiated lutikizumab in Period 2 will then be re-randomized to lutikizumab Dose A every other week through Week 52
Period 1PlaceboParticipants will be randomized to either Lutikizumab Dose B at baseline followed by Lutikizumab Dose A, or a matching placebo dose equivalent for both, every week through Week 16 .
Period 2: Lutikizumab Every WeekLutikizumabParticipants randomized to lutikizumab in Period 1 who complete Week 16 of the study will be re-randomized to lutikizumab Dose A through Week 52
Period 2: Placebo to Lutikizumab Group Every Other WeekPlaceboThe participants that were assigned Placebo in Period 1 and initiated lutikizumab in Period 2 will then be re-randomized to lutikizumab Dose A every other week through Week 52
Period 2: Lutikizumab Every Other WeekPlaceboParticipants randomized to lutikizumab in Period 1 who complete Week 16 of the study will be re-randomized to lutikizumab Dose A every other week though week 52
Period 2: Placebo to Lutikizumab GroupLutikizumabParticipants randomized to Placebo in Period 1 who complete Week 16 of the study will initiate lutikizumab with Dose B followed by Dose A every week.
Period 2: Lutikizumab Every Other WeekLutikizumabParticipants randomized to lutikizumab in Period 1 who complete Week 16 of the study will be re-randomized to lutikizumab Dose A every other week though week 52
Period 2: Placebo to Lutikizumab Group Every WeekLutikizumabParticipants that were assigned Placebo in Period 1 and initiated lutikizumab in Period 2 will then be re-randomized to lutikizumab Dose A every week through Week 52
Primary Outcome Measures
NameTimeMethod
Number of Participants with Adverse Events (AEs)Up to Approximately Week 62

An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

Percentage of Participants Achieving Hidradenitis Suppurative Clinical Response (HiSCR) 75At Week 16

HiSCR 75 is defined as at least a 75% reduction from baseline in the total abscess and inflammatory nodule (AN) count, with no increase in abscess count and no increase in draining fistula count relative to baseline.

Secondary Outcome Measures
NameTimeMethod
Percentage of Participants Achieving Numeric Rating Scale (NRS) 30 among Participants with Baseline NRS >=3At Week 8

NRS 30 is defined as at least a 30% reduction and at least 1-unit reduction from Baseline in worst skin pain (maximal daily pain), as assessed by the Patient's Global Assessment (PGA) of Skin Pain.

Change from Baseline in Dermatology Life Quality Index (DLQI)At Week 16

DLQI (Dermatology Life Quality Index) assesses symptoms and impacts of dermatologic diseases on quality of life. DLQI scores range from 0 (no effect) to 30 (very large effect), with a higher score indicating a more impaired quality of life.

Change from Baseline in Hidradenitis Suppurativa Impact Assessment (HSIA)At Week 16

The HSIA is an 18-item PRO questionnaire developed to assess the impact of HS on the daily lives of subjects in the 7 days prior to the assessment. Items 1 - 16 of the HSIA are scored on a 0 to 10 NRS, where 0 represents no impact and 10 represents extreme impact.

Change from Baseline in Hidradenitis Suppurativa Symptom Assessment (HSSA) Worst Drainage ScoreAt Week 16

The HSSA (24-hour recall) is a 9-item PRO questionnaire developed to assess the primary symptoms of Hidradenitis Suppurativa (HS) in the 7 consecutive days prior to assessments. Each item of the HSSA is scored on an 11-point (0 to 10) NRS, where 0 represents no symptoms and 10 represents extreme symptom experience.

Change from Baseline in Draining Fistula CountAt Week 16
Percentage of Participants Achieving HiSCR 90At Week 16

HiSCR 90 is defined as at least a 90% reduction from baseline in the total abscess and inflammatory nodule (AN) count, with no increase in abscess count and no increase in draining fistula count relative to baseline.

Change from Baseline in the Patient's Global Assessment of HS-related Skin Pain (NRS)At Week 8
Change from Baseline in HSSAAt Week 16

The HSSA (24-hour recall) is a 9-item PRO questionnaire developed to assess the primary symptoms of Hidradenitis Suppurativa (HS) in the 7 consecutive days prior to assessments. Each item of the HSSA is scored on an 11-point (0 to 10) NRS, where 0 represents no symptoms and 10 represents extreme symptom experience.

Change from Baseline in the Patient's Global Assessment of HS-related Odor (smell), based on the HSSA Question 8At Week 16

The HSSA (24-hour recall) is a 9-item PRO questionnaire developed to assess the primary symptoms of HS in the 7 consecutive days prior to assessments. Each item of the HSSA is scored on an 11-point (0 to 10) NRS, where 0 represents no symptoms and 10 represents extreme symptom experience.

Percentage of Participants with an Occurrence of HS Flare in Period 1Baseline to Week 16

HS Flare is defined as at least one occurrence of a ≥ 25% increase in AN count with a minimum absolute increase of 2 relative to Baseline.

Trial Locations

Locations (214)

Cahaba Dermatology & Skin Health Center /ID# 263795

🇺🇸

Birmingham, Alabama, United States

Medical Dermatology Specialists /ID# 263394

🇺🇸

Phoenix, Arizona, United States

Dermatology Trial Associates /ID# 264587

🇺🇸

Bryant, Arkansas, United States

Arkansas Research Trials /ID# 263901

🇺🇸

North Little Rock, Arkansas, United States

Joseph Raoof Md,Inc /Id# 263756

🇺🇸

Encino, California, United States

Dermatology Research Associates - Los Angeles /ID# 263765

🇺🇸

Los Angeles, California, United States

Stanford University School of Medicine - Redwood City /ID# 263711

🇺🇸

Redwood City, California, United States

Integrative Skin Science and Research /ID# 264600

🇺🇸

Sacramento, California, United States

Clinical Trials Research Institute /ID# 263743

🇺🇸

Thousand Oaks, California, United States

Clearlyderm Dermatology - West Boca /ID# 265023

🇺🇸

Boca Raton, Florida, United States

Apex Clinical Trials /ID# 263815

🇺🇸

Brandon, Florida, United States

TrueBlue Clinical Research /ID# 265041

🇺🇸

Brandon, Florida, United States

Skin Care Research - Hollywood /ID# 263805

🇺🇸

Hollywood, Florida, United States

GSI Clinical Research, LLC /ID# 263827

🇺🇸

Margate, Florida, United States

Sullivan Dermatology /ID# 263511

🇺🇸

Miami, Florida, United States

Renstar Medical Research - Ocala - Northeast 1st Avenue /ID# 263842

🇺🇸

Ocala, Florida, United States

Skin Care Research - Tampa /ID# 263819

🇺🇸

Tampa, Florida, United States

Advanced Clinical Research Institute /ID# 263808

🇺🇸

Tampa, Florida, United States

Alliance Clinical Research of Tampa /ID# 264594

🇺🇸

Tampa, Florida, United States

Centricity Research Columbus Dermatology /ID# 266530

🇺🇸

Columbus, Georgia, United States

Cleaver Medical Group Dermatology /ID# 263845

🇺🇸

Dawsonville, Georgia, United States

Treasure Valley Medical Research /ID# 263671

🇺🇸

Boise, Idaho, United States

Northwestern University Feinberg School of Medicine /ID# 265007

🇺🇸

Chicago, Illinois, United States

Arlington Dermatology /ID# 263410

🇺🇸

Rolling Meadows, Illinois, United States

Dawes Fretzin, LLC /ID# 264601

🇺🇸

Indianapolis, Indiana, United States

Dermatology Partners of Leawood /ID# 263533

🇺🇸

Leawood, Kansas, United States

Equity Medical, LLC /ID# 268590

🇺🇸

Bowling Green, Kentucky, United States

Dermatology Specialists Research (DS Research) - Kentucky /ID# 263343

🇺🇸

Louisville, Kentucky, United States

Hamzavi Dermatology - Canton /ID# 263538

🇺🇸

Canton, Michigan, United States

Michigan Center for Medical Research /ID# 263547

🇺🇸

Clarkston, Michigan, United States

Dermatology and Skin Center of Lees Summit /ID# 263567

🇺🇸

Lee's Summit, Missouri, United States

MediSearch Clinical Trials /ID# 263582

🇺🇸

Saint Joseph, Missouri, United States

Vivida Dermatology- Flamingo /ID# 263716

🇺🇸

Las Vegas, Nevada, United States

Dartmouth Hitchcock Medical Center - Old Etna Road /ID# 263713

🇺🇸

Lebanon, New Hampshire, United States

ActivMed Practice and Research, LLC /ID# 263387

🇺🇸

Portsmouth, New Hampshire, United States

Mount Sinai Doctors - Dermatology /ID# 264602

🇺🇸

New York, New York, United States

Atrium Health Wake Forest Baptist Medical Center /ID# 264507

🇺🇸

Winston-Salem, North Carolina, United States

Dermatology of Greater Columbus /ID# 263497

🇺🇸

Bexley, Ohio, United States

University Hospitals Cleveland Medical Center /ID# 263600

🇺🇸

Cleveland, Ohio, United States

Ohio State Officenter Gahanna /ID# 263598

🇺🇸

Gahanna, Ohio, United States

Dermatologists of Southwest Ohio - Mason /ID# 263588

🇺🇸

Mason, Ohio, United States

Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 263076

🇩🇪

Berlin, Germany

Apex Clinical Research Center /ID# 272787

🇺🇸

Mayfield Heights, Ohio, United States

Dermatology Partners /ID# 264999

🇺🇸

Philadelphia, Pennsylvania, United States

University of Pittsburgh Medical Center /ID# 264590

🇺🇸

Pittsburgh, Pennsylvania, United States

Clinical Research Center of the Carolinas /ID# 263407

🇺🇸

Charleston, South Carolina, United States

Medical University of South Carolina /ID# 263890

🇺🇸

Charleston, South Carolina, United States

ADCS - Spartanburg /ID# 267207

🇺🇸

Spartanburg, South Carolina, United States

Arlington Research Center, Inc /ID# 263895

🇺🇸

Arlington, Texas, United States

Bellaire Dermatology Associates /ID# 263850

🇺🇸

Bellaire, Texas, United States

Studies in Dermatology LLC /ID# 263399

🇺🇸

Cypress, Texas, United States

Reveal Research Institute, Dallas /ID# 267233

🇺🇸

Dallas, Texas, United States

Center for Clinical Studies - Houston - Binz Street /ID# 263378

🇺🇸

Houston, Texas, United States

Texas Dermatology Research Center /ID# 264488

🇺🇸

Plano, Texas, United States

Texas Dermatology and Laser Specialists /ID# 263778

🇺🇸

San Antonio, Texas, United States

Dermatology Associates of Tyler /ID# 265002

🇺🇸

Tyler, Texas, United States

University of Utah /ID# 263818

🇺🇸

Murray, Utah, United States

Virginia Clinical Research /ID# 264553

🇺🇸

Norfolk, Virginia, United States

Dermatology Specialists of Spokane /ID# 264499

🇺🇸

Spokane, Washington, United States

Paratus Clinical Research Woden /ID# 263125

🇦🇺

Phillip, Australian Capital Territory, Australia

Momentum Clinical Research /ID# 263192

🇦🇺

Darlinghurst, New South Wales, Australia

Premier Dermatology /ID# 263124

🇦🇺

Kogarah, New South Wales, Australia

Veracity Clinical Research /ID# 263126

🇦🇺

Woolloongabba, Queensland, Australia

Sinclair Dermatology - Melbourne /ID# 263121

🇦🇺

East Melbourne, Victoria, Australia

Medizinische Universitaet Graz /ID# 263306

🇦🇹

Graz, Steiermark, Austria

Medizinische Universitaet Wien /ID# 264043

🇦🇹

Wien, Austria

FACET Dermatology /ID# 265267

🇨🇦

Toronto, Ontario, Canada

Universite Libre de Bruxelles - Hopital Erasme /ID# 263097

🇧🇪

Anderlecht, Bruxelles-Capitale, Belgium

Cliniques Universitaires UCL Saint-Luc /ID# 263096

🇧🇪

Bruxelles, Bruxelles-Capitale, Belgium

Universitair Ziekenhuis Brussel /ID# 263101

🇧🇪

Jette, Bruxelles-Capitale, Belgium

Grand Hopital de Charleroi - I.M.T.R /ID# 263100

🇧🇪

Charleroi, Hainaut, Belgium

CHU de Liège /ID# 263095

🇧🇪

Liège, Liege, Belgium

UZ Gent /ID# 263099

🇧🇪

Gent, Oost-Vlaanderen, Belgium

Universitair Ziekenhuis Leuven /ID# 263098

🇧🇪

Leuven, Vlaams-Brabant, Belgium

Klinicki centar Banja Luka /ID# 265909

🇧🇦

Banja Luka, Republika Srpska, Bosnia and Herzegovina

Acibadem City Clinic Tokuda Hospital /ID# 263300

🇧🇬

Sofiya, Sofia, Bulgaria

ASMC-IPSMC-Skin and Venereal Diseases /ID# 262891

🇧🇬

Sofiya, Sofia, Bulgaria

Medical Center Hera EOOD /ID# 263010

🇧🇬

Sofiya, Sofia, Bulgaria

Medical Center Cordis /ID# 262894

🇧🇬

Pleven, Bulgaria

Diagnostic consultative center Focus-5 /ID# 262893

🇧🇬

Sofiya, Bulgaria

UMHAT Professor Stoyan Kirkovich /ID# 262892

🇧🇬

Stara Zagora, Bulgaria

Beacon Dermatology Inc /ID# 264262

🇨🇦

Calgary, Alberta, Canada

Rejuvenation Dermatology - Edmonton Downtown /ID# 265963

🇨🇦

Edmonton, Alberta, Canada

Stratica Dermatology /ID# 265856

🇨🇦

Edmonton, Alberta, Canada

Interior Dermatology Centre - Probity - PPDS /ID# 266202

🇨🇦

Kelowna, British Columbia, Canada

Brunswick Dermatology Center /ID# 264260

🇨🇦

Fredericton, New Brunswick, Canada

Karma Clinical Trials /ID# 265962

🇨🇦

St. John's, Newfoundland and Labrador, Canada

Leader Research /ID# 266114

🇨🇦

Hamilton, Ontario, Canada

DermEffects /ID# 265262

🇨🇦

London, Ontario, Canada

Derm Care Clinic /ID# 265261

🇨🇦

Mississauga, Ontario, Canada

SKiN Centre for Dermatology /ID# 267735

🇨🇦

Peterborough, Ontario, Canada

York Dermatology Clinic & Research Centre /ID# 265265

🇨🇦

Richmond Hill, Ontario, Canada

Private Practice - Dr. Kim Papp Clinical Research /ID# 265266

🇨🇦

Waterloo, Ontario, Canada

Diex Recherche Québec /ID# 265263

🇨🇦

Québec, Quebec, Canada

Centre de Recherche Saint-Louis /ID# 265855

🇨🇦

Québec, Quebec, Canada

Private Practice - Dr. Angelique Gagne-Henley /ID# 264263

🇨🇦

St-Jérôme, Quebec, Canada

SkinSense Dermatology /ID# 265964

🇨🇦

Saskatoon, Saskatchewan, Canada

Specialty hospital Medico /ID# 263922

🇭🇷

Rijeka, Croatia

Fakultní nemocnice Ostrava /ID# 264041

🇨🇿

Ostrava, Ostrava-mesto, Czechia

Karlovarska Krajska Nemocnice - Karlovy Vary /ID# 265354

🇨🇿

Karlovy Vary, Czechia

Herlev and Gentofte Hospital /ID# 265839

🇩🇰

Hellerup, Hovedstaden, Denmark

Aarhus Universitetshospital - Skejby /ID# 265657

🇩🇰

Aarhus, Midtjylland, Denmark

Hopital Edouard Herriot /ID# 263456

🇫🇷

Lyon, Auvergne-Rhone-Alpes, France

Centre Hospitalier Universitaire de Saint Etienne - Hopital Nord /ID# 263459

🇫🇷

St-Priest-en-Jarez, Loire, France

Centre Hospitalier Universitaire de Rouen (CHU)- Hopital Charles Nicolle /ID# 263995

🇫🇷

Rouen, Seine-Maritime, France

Groupe Hospitalier Paris Saint-Joseph /ID# 263996

🇫🇷

Paris, France

Polyclinique Courlancy /ID# 263313

🇫🇷

Reims, France

Universitaetsklinikum Freiburg /ID# 263659

🇩🇪

Freiburg, Baden-Wuerttemberg, Germany

Universitaetsklinikum Tuebingen /ID# 271718

🇩🇪

Tübingen, Baden-Wuerttemberg, Germany

Universitaetsklinikum Erlangen /ID# 263075

🇩🇪

Erlangen, Bayern, Germany

Beldio Research GmbH /ID# 263074

🇩🇪

Memmingen, Bayern, Germany

Rosenpark Research /ID# 269202

🇩🇪

Darmstadt, Hessen, Germany

Fachklinik Bad Bentheim /ID# 263067

🇩🇪

Bad Bentheim, Niedersachsen, Germany

Katholisches Klinikum Bochum /ID# 262976

🇩🇪

Bochum, Nordrhein-Westfalen, Germany

Universitaetsklinikum Muenster /ID# 263068

🇩🇪

Muenster, Nordrhein-Westfalen, Germany

Hautarztpraxis Mortazawi /ID# 271673

🇩🇪

Remscheid, Nordrhein-Westfalen, Germany

Hautarztpraxis Dr. Kirschner /ID# 263656

🇩🇪

Mainz, Rheinland-Pfalz, Germany

University General Hospital Attikon /ID# 263413

🇬🇷

Athens, Attiki, Greece

General Hospital Andreas Syggros /ID# 263417

🇬🇷

Athens, Attiki, Greece

Hospital of Skin and Venereal Diseases- Thessaloniki /ID# 263416

🇬🇷

Thessaloniki, Greece

Papageorgiou General Hospital /ID# 263415

🇬🇷

Thessaloniki, Greece

Debreceni Egyetem-Klinikai Kozpont /ID# 263423

🇭🇺

Debrecen, Hajdu-Bihar, Hungary

Semmelweis Egyetem /ID# 263451

🇭🇺

Budapest, Hungary

Pécsi Tudományegyetem /ID# 264120

🇭🇺

Pécs, Hungary

Our Lady of Lourdes Hospital - Drogheda /ID# 265893

🇮🇪

Drogheda, Louth, Ireland

South Infirmary Victoria University Hospital /ID# 265872

🇮🇪

Cork, Ireland

University College Dublin /ID# 265875

🇮🇪

Dublin, Ireland

Mater Misericordiae University Hospital /ID# 265914

🇮🇪

Dublin, Ireland

HaEmek Medical Center /ID# 267297

🇮🇱

Afula, H_efa, Israel

Rambam Health Care Campus /ID# 262994

🇮🇱

Haifa, H_efa, Israel

Rabin Medical Center /ID# 262992

🇮🇱

Petah Tikva, HaMerkaz, Israel

Galilee Medical Center /ID# 262995

🇮🇱

Naharia, HaTsafon, Israel

The Chaim Sheba Medical Center /ID# 262993

🇮🇱

Ramat Gan, Tel-Aviv, Israel

Tel Aviv Sourasky Medical Center /ID# 266581

🇮🇱

Tel Aviv, Tel-Aviv, Israel

Hadassah Medical Center-Hebrew University /ID# 262884

🇮🇱

Jerusalem, Israel

AZIENDA USL TOSCANA CENTRO - Ospedale Piero Palagi /ID# 263454

🇮🇹

Florence, Firenze, Italy

Azienda Ospedaliera Universitaria Federico II /ID# 263539

🇮🇹

Naples, Napoli, Italy

Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 263473

🇮🇹

Rome, Roma, Italy

AOU Policlinico G. Rodolico - San Marco /ID# 263469

🇮🇹

Catania, Italy

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico /ID# 263471

🇮🇹

Milano, Italy

Nagoya City University Hospital /ID# 263874

🇯🇵

Nagoya, Aichi, Japan

Fujita Health University Hospital /ID# 265440

🇯🇵

Toyoake, Aichi, Japan

Takagi Dermatological Clinic /ID# 264810

🇯🇵

Obihiro-Shi, Hokkaido, Japan

Iwate Medical University Uchimaru Medical Center /ID# 273799

🇯🇵

Morioka, Iwate, Japan

University Hospital Kyoto Prefectural University of Medicine /ID# 264291

🇯🇵

Kyoto-shi, Kyoto, Japan

University of the Ryukyus Hospital /ID# 264605

🇯🇵

Ginowan-shi, Okinawa, Japan

Osaka Metropolitan University Hospital /ID# 265682

🇯🇵

Osaka-shi, Osaka, Japan

Kindai University Hospital /ID# 264322

🇯🇵

Osakasayama-shi, Osaka, Japan

Dokkyo Medical University Saitama Medical Center /ID# 265400

🇯🇵

Koshigaya, Saitama, Japan

Fukuoka University Hospital /ID# 263991

🇯🇵

Fukuoka, Japan

Nihon University Itabashi Hospital /ID# 264661

🇯🇵

Tokyo, Japan

SoonChunHyang University Hospital Cheonan /ID# 271320

🇰🇷

Cheonan-si, Chungcheongnamdo, Korea, Republic of

Korea University Ansan Hospital /ID# 264227

🇰🇷

Ansan-si, Gyeonggido, Korea, Republic of

CHA Bundang Medical Center /ID# 264225

🇰🇷

Seongnam, Gyeonggido, Korea, Republic of

Yonsei University Health System Severance Hospital /ID# 271353

🇰🇷

Seoul, Seoul Teugbyeolsi, Korea, Republic of

SoonChunHyang University Seoul Hospital /ID# 264224

🇰🇷

Seoul, Seoul Teugbyeolsi, Korea, Republic of

Asan Medical Center /ID# 264228

🇰🇷

Seoul, Seoul Teugbyeolsi, Korea, Republic of

Hallym University Kangnam Sacred Heart Hospital /ID# 264226

🇰🇷

Seoul, Seoul Teugbyeolsi, Korea, Republic of

Erasmus Medisch Centrum /ID# 263377

🇳🇱

Rotterdam, Zuid-Holland, Netherlands

Clinical Trials New Zealand /ID# 265432

🇳🇿

Hamilton, Waikato, New Zealand

Greenlane Clinical Centre /ID# 263191

🇳🇿

Auckland, New Zealand

Stavanger Universitetssykehus /ID# 265997

🇳🇴

Stavanger, Rogaland, Norway

Universitetssykehuset I Nord-Norge /ID# 265992

🇳🇴

Tromsø, Troms, Norway

Oslo University Hospital - Rikshospitalet /ID# 265996

🇳🇴

Oslo, Norway

Oftalmika sp. z o.o. /ID# 263087

🇵🇱

Bydgoszcz, Kujawsko-pomorskie, Poland

DERMED Centrum Medyczne Sp. z o.o /ID# 263147

🇵🇱

Lodz, Lodzkie, Poland

Santa Sp. z o..o. Santa Familia PTG Lodz /ID# 263181

🇵🇱

Lodz, Lodzkie, Poland

Centrum Nowoczesnych Terapii 'Dobry Lekarz' sp.z.o.o. /ID# 263146

🇵🇱

Krakow, Malopolskie, Poland

Klinika Ambroziak Dermatologia /ID# 263173

🇵🇱

Warszawa, Mazowieckie, Poland

Unidade Local de Saude do Alto Ave, EPE /ID# 265158

🇵🇹

Guimaraes, Braga, Portugal

CUF Descobertas Hospital /ID# 263188

🇵🇹

Lisbon, Lisboa, Portugal

Unidade Local de Saude de Sao Jose, EPE /ID# 265155

🇵🇹

Lisboa, Portugal

Unidade Local de Saude de Santo Antonio, E.P.E. /ID# 265479

🇵🇹

Porto, Portugal

Private Practice - Dr. Alma Cruz /ID# 263204

🇵🇷

Carolina, Puerto Rico

Clinical Research Puerto Rico /ID# 263450

🇵🇷

San Juan, Puerto Rico

Private Practice - Dr. Orasan Remus /ID# 263305

🇷🇴

Cluj Napoca, Cluj, Romania

Spitalul Clinic Colentina /ID# 263303

🇷🇴

Bucharest, Romania

Centrul Medical Euromed /ID# 263304

🇷🇴

Bucharest, Romania

Military Medical Academy /ID# 263257

🇷🇸

Belgrade, Beograd, Serbia

University Clinical Center Serbia /ID# 263256

🇷🇸

Belgrade, Beograd, Serbia

University Clinical Center Kragujevac /ID# 264211

🇷🇸

Kragujevac, Sumadijski Okrug, Serbia

University Clinical Center Vojvodina /ID# 263260

🇷🇸

Novi Sad, Serbia

National University Hospital /ID# 264673

🇸🇬

Singapore, Singapore

National Skin Centre /ID# 264680

🇸🇬

Singapore, Singapore

Univerzitna nemocnica L. Pasteura Kosice /ID# 263907

🇸🇰

Košice, Kosicky Kraj, Slovakia

Fakultna nemocnica s poliklinikou Nove Zamky /ID# 265944

🇸🇰

Nové Zámky, Nitriansky Kraj, Slovakia

Poliklinika Bezrucova (Cliniq s.r.o.) /ID# 263921

🇸🇰

Bratislava, Slovakia

Fakultna nemocnica Trnava /ID# 263905

🇸🇰

Trnava, Slovakia

University Medical Centre Ljubljana /ID# 265720

🇸🇮

Ljubljana, Slovenia

University Medical Centre Maribor /ID# 265827

🇸🇮

Maribor, Slovenia

Global Clinical Trials /ID# 262839

🇿🇦

Pretoria, Gauteng, South Africa

Life Chatsmed Garden Hospital /ID# 270237

🇿🇦

Chatsworth, Kwazulu-Natal, South Africa

Ahmed Al-Kadi Private Hospital /ID# 262837

🇿🇦

Durban, Kwazulu-Natal, South Africa

Dr Ahmed Ismail Manjra /ID# 262838

🇿🇦

Westville, Kwazulu-Natal, South Africa

Hospital Universitari Parc Tauli /ID# 262942

🇪🇸

Sabadell, Barcelona, Spain

Hospital Universitario Marqués de Valdecilla /ID# 263039

🇪🇸

Santander, Cantabria, Spain

Hospital Universitario Virgen de la Victoria /ID# 262941

🇪🇸

Málaga, Malaga, Spain

Hospital de Manises /ID# 262938

🇪🇸

Manises, Valencia, Spain

Hospital General Universitario Gregorio Marañón /ID# 262940

🇪🇸

Madrid, Spain

Consorci Hospital General Universitario de Valencia /ID# 262944

🇪🇸

Valencia, Spain

Karolinska University Hospital Solna /ID# 264530

🇸🇪

Solna, Stockholms Lan, Sweden

Universitetssjukhuset Örebro /ID# 265064

🇸🇪

Örebro, Sweden

Dermatology & Skin Care Clinic /ID# 264030

🇨🇭

Buochs, Nidwalden, Switzerland

Kantonsspital St.Gallen /ID# 264238

🇨🇭

St. Gallen, Sankt Gallen, Switzerland

University Hospital Zurich /ID# 266142

🇨🇭

Zurich, Zuerich, Switzerland

Kaohsiung Chang Gung Memorial Hospital /ID# 264619

🇨🇳

Kaohsiung City, Kaohsiung, Taiwan

National Taiwan University Hospital /ID# 264618

🇨🇳

Taipei City, Taipei, Taiwan

Taichung Veterans General Hospital /ID# 270741

🇨🇳

Taichung, Taiwan

Mackay Memorial Hospital /ID# 263661

🇨🇳

Taipei City, Taiwan

Taipei Veterans General Hospital /ID# 265879

🇨🇳

Taipei City, Taiwan

Linkou Chang Gung Memorial Hospital /ID# 264620

🇨🇳

Taoyuan City, Taiwan

Queen Margaret Hospital /ID# 264198

🇬🇧

Dunfermline, Fife, United Kingdom

Barts Health NHS Trust /ID# 264121

🇬🇧

London, Greater London, United Kingdom

Harrogate District Hospital /ID# 265632

🇬🇧

Harrogate, North Yorkshire, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath